Symproic FDA Approval History
FDA Approved: Yes (First approved March 23, 2017)
Brand name: Symproic
Generic name: naldemedine
Dosage form: Tablets
Company: Shionogi Inc.
Treatment for: Opioid-Induced Constipation
Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.
Development timeline for Symproic
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
